Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers
These findings suggest that CCL-106 and its epimers hold potential as effective and less-toxic therapeutic options for PDAC treatment. Further clinical studies are warranted to explore their translational application.
Authors
- Westley Cruces (ORCID: https://orcid.org/0000-0003-3023-7626)
- A.C. Collins (ORCID: https://orcid.org/0000-0003-0503-3429)
- Tarik Hadid (ORCID: https://orcid.org/0000-0002-5423-4211)
- Asfar S. Azmi (ORCID: https://orcid.org/0000-0003-1178-9505)
- Husain Yar Khan (ORCID: https://orcid.org/0000-0002-9161-1514)
- Amro Aboukameel
- Tesfay Tesfatsion (ORCID: https://orcid.org/0000-0002-3743-9522)
- Mohammed Najeeb Al Hallak (ORCID: https://orcid.org/0000-0002-4598-8177)
- Maite L. Docampo Palacios (ORCID: https://orcid.org/0000-0001-5205-3989)
- Prakash G. Jagtap
- Yousef Mzannar
- Krishanu Ray (ORCID: https://orcid.org/0000-0001-6406-3199)
- Giuseppe A. Ramirez (ORCID: https://orcid.org/0000-0002-2889-366X)
- Sarah Motorwala
Institutions
- Wayne State University (US)
- Blackstone (United States) (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Research Institute for Chromatography (BE)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100211
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00